Text Size

Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2004 by National Center for Research Resources (NCRR).
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Center for Research Resources (NCRR)
ClinicalTrials.gov Identifier:
NCT00006199
First received: September 9, 2000
Last updated: June 23, 2005
Last verified: January 2004
History of Changes
  Purpose

The purpose of this clinical trial is to establish the safest doses for the combination of a farnesyl transferase inhibitor, R115777 plus topotecan in patients with advanced solid tumors, previously treated or beyond standard therapy of clinical benefit. Maximum tolerated dose, dose limiting toxicity and the activity of this combination will be assessed.

This chemotherapy regimen is a two-pronged attack at the way cancer cells replicate. R115777 is a compound that may inhibit cancer cell growth by interfering with the p21 ras oncogene, while topotecan, a topoisomerase-1 inhibitor, works on cancer cells not subject to control by the ras oncogene. Animal studies suggest that the combination may be synergistic. Another advantage is that R115777 can be taken by mouth.


Condition Intervention Phase
Cancer
 Drug: R115777 (farnesyl transferase inhibitor)
Drug: Topotecan
 Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:

MedlinePlus related topics: Cancer
U.S. FDA Resources

Further study details as provided by National Center for Research Resources (NCRR):

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with advanced solid tumors with previous treatment or beyond standard therapy of significant clinical benefit
  • Therapy with no more than 3 prior chemotherapy regimens
  • Radiotherapy to less than 25% of bone marrow volume (no pelvic radiation)
  • Adequate organ function
  • Recovery from the effects of prior chemotherapy and radiation therapy, with at least a 4 week interval. All prior toxicities should have resolved to baseline prior to entry into the study.
  • Good performance status
  • Anticipate life expectancy of at least 6 months
  • Not pregnant or lactating.
  • Sexually active men and women of childbearing age must use adequate contraception.
  • Be able to give signed, written informed consent.
  • No gastrointestinal condition that could affect the absorption of the drug
  • No active infection requiring systemic medical therapy one week prior to chemotherapy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00006199

Contacts
Contact: Anita Tierney 1-212-263-2173

Locations
United States, New York
NYU Cancer Institute Recruiting
New York, New York, United States, 10016
Contact: Anita Tierney     212-263-2173        
Sponsors and Collaborators
National Center for Research Resources (NCRR)
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00006199     History of Changes
Other Study ID Numbers: NCRR-M01RR00096-1001, M01RR00096
Study First Received: September 9, 2000
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Keywords provided by National Center for Research Resources (NCRR):
solid tumor

Additional relevant MeSH terms:
Topotecan
Tipifarnib
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
 Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on June 18, 2013